Screener
Prime Medicine PRME Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Prime Medicine’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053883
FAQ
- What is Prime Medicine's cash & equivalents?
- Prime Medicine (PRME) reported cash & equivalents of $61.14M in Q2 2026.
- How has Prime Medicine's cash & equivalents changed year-over-year?
- Prime Medicine's cash & equivalents decreased by 9.4% year-over-year, from $67.5M to $61.14M.
- What is the long-term trend for Prime Medicine's cash & equivalents?
- Over 5 years (2020 to 2025), Prime Medicine's cash & equivalents has grown at a 15.7% compound annual growth rate (CAGR), from $36.98M to $76.72M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Prime Medicine's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude